Suggested remit: To appraise the clinical and cost effectiveness of benralizumab with corticosteroids within its marketing authorisation for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6266
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Newcastle NIHR TAR Team, Newcastle University
Stakeholders
- Companies sponsors
- AstraZeneca
- Others
- Department of Health and Social Care
- NHS England
- Health Technology Wales
- Patient carer groups
- Vasculitis UK
- Professional groups
- Association of Respiratory Nurse Specialists
- British Society for Rheumatology
- British Thoracic Society
- Royal College of Physicians
- UK Kidney Association
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- UK and Ireland Vasculitis Rare Disease Group
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 May 2025 | Committee meeting |
| 06 May 2025 | Declaration of interests |
| 30 September 2024 | Invitation to participate |
| 16 July 2024 - 13 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6266 |
| 16 July 2024 | In progress. Scoping commencing |
| 17 May 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2024 when we will write to you about how you can get involved. |
| 18 January 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 18 January 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual